Exhibit 99.1 Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SAN DIEGO, February 26, 2026 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "The past year marked a period of significant execution and progress for Janux as we continu ...

Exhibit 99.1 Aeva Reports Fourth Quarter and Full Year 2025 Results 2026 Financial Outlook • Revenue in the range of $30 million to $36 million, representing growth of approximately 70% to 100% year-over-year Awarded Major Global Production Contract from Top 10 Passenger OEM Selected by Top 5 Passenger OEM for Global Vehicle Development Program Nvidia Selected Aeva as Reference LiDAR Sensor for DRIVE Hyperion Platform Doubled Revenue in 2025 Driven by Scaling Volume and New Markets Expansion MOUNTAIN VIEW, ...

Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximate ...

Exhibit 99.1 FOR IMMEDIATE RELEASE: Investor Contact: Tom Line—Chief Financial Officer 614-255-5989 (tline@diamond-hill.com) DIAMOND HILL INVESTMENT GROUP, INC. REPORTS 2025 FINANCIAL RESULTS COLUMBUS, Ohio - February 26, 2026 -- Diamond Hill Investment Group, Inc. (Nasdaq: DHIL) today reported financial results for the fourth quarter and year ended December 31, 2025. • Assets under management ("AUM") and assets under advisement ("AUA") combined were $31.0 billion, compared to $31.9 billion as of December 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36153 Criteo S.A. (Exact name of registrant as specified in its charter) | France | | Not Applicable | | --- | --- | --- | | (State ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q | ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | | --- | | For the quarterly period ended January 31, 2026 | | OR | | ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | | For the transition period from ____________ to ____________ . | | Commission File Number 0-21180 | | INTUIT INC. ...

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025 Fourth quarter and full year 2025 revenue exceeded guidance Framingham, MA (February 26, 2026) – Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Full Year 2025 Financial Highligh ...

Table of Contents | United States | I | | --- | --- | | Securities and Exchange Commission | | | Washington, D.C. 20549 | | | Form 10-K | | | (Mark One)concent | | | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2025 | | | or | | | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from to | | | Commission file number 000-24498 | | | DIAMOND HILL INVES ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-14798 American Woodmark Corporation (Exact name of registrant as specified in its charter) Vi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 Miami, FL 33137 (Address of Principal Executive Offices) (Zip Code) (305) 575-4100 (Registrant's Telephone N ...